Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(25)
•••
Comment by Blazesbon Jun 15, 2020 7:40pm
196 Views
Post# 31153546

RE:RE:RE:How Significant is 'Significant'

RE:RE:RE:How Significant is 'Significant'
WalkOverTheStrt wrote: So your logic is b/c 346 worked but the patients took Tylenol afterwards that the entire trial and drug is an issue. The trial results weren't runied. You are focusing on an interaction from acetaminophen that is caused by .... get this... acetaminophen.... 
Your critical thinking lack the critical and thinking part....
 As you say 'the entire trial and drug is an issue' but it's not an issue for me.  The response by management to the acetaminophin is an issue.  Got that?

I'll spell it out for you.  Because acetaminophin is, in management's words, 'significant' a decision to sell one quarter of the company was made largely at .40 per share with warrants for .60.  This at a time when the shares were .70.  Got that?

Management also did a little front running unloading of personal shares before the 'significant' acetaminopen news was released.  Got that?


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities